Skip to content
DataLookout
Menu

NCT05276011

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below.

  1. Notable Primary and study completion pushed from Oct 2027 to Oct 2028
    • Start date: Oct 2026 to Oct 2027
    v7
  2. Notable Primary and study completion dates: Oct 2026 to Oct 2027
    • Start date: Oct 2025 to Oct 2026
    v6
  3. Notable Primary and study completion dates: Oct 2025 to Oct 2026
    • Start date: Oct 2024 to Oct 2025
    v5
  4. Notable Primary and study completion dates: Oct 2024 to Oct 2025
    • Start date: Oct 2023 to Oct 2024
    v4
  5. Notable Primary and study completion dates: Oct 2023 to Oct 2024
    • Start date: Oct 2022 to Oct 2023
    v3
  6. Minor Secondary endpoints: details revised at 1 of 5 entriesv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Hip Pain as Assessed by VAS
Timeframe: Baseline to Month 12

Secondary (5)

Hip Disability and Osteoarthritis Outcome Score (HOOS)
Timed Up and Go Test (TUG)
UCLA Activity Score
Joint Space Width (JSW) on standing X-ray
WOMAC® (Western Ontario and McMaster Universities Osteoarthritis Index) total score

Arms and interventions

Active Treatment (TG-C)Active comparator

TG-C at 1.0 x 10e7 cells per single 2 mL intraarticular injection

Active Treatment 2 (TG-C)Active comparator

TG-C at 3.0 x 10e6 cells per single 2 mL intraarticular injection

Placebo Control (Normal Saline)Placebo comparator

Normal saline, single 2 mL intraarticular injection

Biologicals: TG-C, Placebo Control